Default company panoramic image

Mobius Therapeutics, LLC

The only FDA approved formulation of mitomycin-c with an ophthalmic indication. Orphan drug status. Patent exclusivity until 2029.

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded April 2006
  • Employees 9
  • Website

Company Summary

Mobius has developed a patent protected system, Mitosol®, for delivering mitomycin-c in glaucoma, refractive, and pterygium surgeries. Mobius gained FDA approval in 2012 for glaucoma and is pursuing additional indications. Mitosol® enhances OR safety and is stored at room temperature; shelf life grows from 14 days to 2 years vs compounding. Potency is assured and technique is unchanged. Mitosol is reimbursed whereas compounded MMC is not.


  • Default avatar
    Edward Jerome Timm
    President and CEO

     25 years’ in the medical/surgical device industry
     Founded or led franchises for multiple companies:
     American Hospital Supply Corp; Applied Medical Resources Corporation; Storz Ophthalmics; and Given Imaging.
     Responsible for Commercial Development at Synergetics, Inc.
     Took from startup to IPO, operating in sixty countries and two disciplines
     BA, Philosophy, University of Dayton
     11 issued US patents, with numerous patents pending

  • Default avatar
    Mark W. Wright
    Chief Financial Officer

     Finance executive with significant experience in venture capital backed, rapid growth, life science, and technology companies
     Served as a CFO and board member of several companies, including:
     BrainScope Company, Inc.; Everest Biomedical I n s t r u m e n t s Company; Abiliti Solutions, Inc.; and Technology Applications, Inc.
     Certified Public Accountant
     BSBA from Saint Louis University


  • Default avatar
    Thompson Coburn
    Default avatar
    Rubin Brown

Previous Investors

  • Default avatar
    Default avatar